Pfizer Inc. (PFE)
Pre-market:
| Previous close | 26.00 |
| Open | 26.00 |
| Bid | 26.34 x 3100 |
| Ask | 26.36 x 2200 |
| Day's range | 25.92 - 26.50 |
| 52-week range | 25.23 - 40.37 |
| Volume | |
| Avg. volume | 42,881,541 |
| Market cap | 148.698B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 70.97 |
| EPS (TTM) | 0.37 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | 1.68 (6.40%) |
| Ex-dividend date | 25 Jan 2024 |
| 1y target est | 29.18 |
ReutersPfizer vs Moderna battle over COVID vaccine patents begins in UK
Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday. Pfizer and its German partner BioNTech sued Moderna at London's High Court in September 2022, seeking to revoke patents held by Moderna, which hit back days later alleging its patents had been infringed. Moderna says Pfizer and BioNTech copied mRNA advances it had pioneered and patented well before the COVID-19 pandemic began in late 2019.
ZacksPfizer (PFE) Rises Higher Than Market: Key Facts
Pfizer (PFE) reachead $26.26 at the closing of the latest trading day, reflecting a +1% change compared to its last close.
Business WireEuropean Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
NEW YORK, April 22, 2024--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative
